Reason for request
Indication extension
Summary of opinion
Favourable opinion for reimbursement in the following indication: “KEYTRUDA, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of KEYTRUDA (pembrolizumab), in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is substantial in the indication: “in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
|
Clinical Added Value
| moderate |
Considering:
- demonstration in a randomised, double-blind, phase 3 study (KN-A18 trial, including 56.7% FIGO 2014 stage III - IVA patients) of the superiority of pembrolizumab compared to chemoradiotherapy, for the treatment of FIGO stage IB2-IIB and III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy, in terms of:
- progression-free survival with an HR = 0.70 (95% CI = [0.55; 0.89]; p = 0.002 < the predefined threshold of 0.0172), 7% patients progressed or died in the experimental group versus 29.0% patients in the control group. The median PFS was not reached in either of the two groups.
- overall survival with an HR = 0.67 (95% CI = [0.50; 0.90]; p = 0.0040 < 0.01026), 2% deaths in the experimental group versus 20.5% patients in the control group. The median OS was not reached in either of the two groups.
And despite:
- the absence of any formal conclusion that can be drawn based on the quality of life findings;
- a safety profile deemed to be acceptable compared to chemoradiotherapy but marked by an excess toxicity with grade ≥ 3 AEs reported in 78.3% of patients in the pembrolizumab group and 70.0% of patients in the placebo group). In addition, 20.6% of patients in the pembrolizumab group and 14.9% of patients in the placebo group had an AE resulting in definitive discontinuation of pembrolizumab treatment.
The Committee deems that KEYTRUDA (pembrolizumab) 25 mg/ml, concentrate for solution for infusion, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), provides a moderate clinical added value (CAV III) compared to chemoradiotherapy.
|
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
ncm6PrWsvgeAsznp